ATE326237T1 - Miscmicellen aus lipopeptiden für induzierung einer immunantwort - Google Patents

Miscmicellen aus lipopeptiden für induzierung einer immunantwort

Info

Publication number
ATE326237T1
ATE326237T1 AT98958314T AT98958314T ATE326237T1 AT E326237 T1 ATE326237 T1 AT E326237T1 AT 98958314 T AT98958314 T AT 98958314T AT 98958314 T AT98958314 T AT 98958314T AT E326237 T1 ATE326237 T1 AT E326237T1
Authority
AT
Austria
Prior art keywords
lipopeptide
immune response
miscmiceles
inducting
motif
Prior art date
Application number
AT98958314T
Other languages
English (en)
Inventor
Helene Gras-Masse
Marc Bossus
Guy Lippens
Jean-Michel Wieruszeski
Andre Tartar
Jean-Gerard Guillet
Isabelle Bourgault-Villada
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9514120&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE326237(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Pasteur Institut filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE326237T1 publication Critical patent/ATE326237T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT98958314T 1997-12-03 1998-12-02 Miscmicellen aus lipopeptiden für induzierung einer immunantwort ATE326237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9715246A FR2771640B1 (fr) 1997-12-03 1997-12-03 Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques

Publications (1)

Publication Number Publication Date
ATE326237T1 true ATE326237T1 (de) 2006-06-15

Family

ID=9514120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98958314T ATE326237T1 (de) 1997-12-03 1998-12-02 Miscmicellen aus lipopeptiden für induzierung einer immunantwort

Country Status (10)

Country Link
US (1) US7476386B1 (de)
EP (1) EP1035866B1 (de)
JP (1) JP2002506001A (de)
AT (1) ATE326237T1 (de)
AU (1) AU1440099A (de)
CA (1) CA2312043A1 (de)
DE (1) DE69834574T2 (de)
ES (1) ES2265672T3 (de)
FR (1) FR2771640B1 (de)
WO (1) WO1999027954A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
GB9930591D0 (en) * 1999-12-23 2000-02-16 Univ London Component for vaccine
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
BR0108210A (pt) * 2000-02-04 2002-10-22 Univ Duke Vacina contra o vìrus da imunodeficiência humana
CA2421409A1 (fr) * 2000-09-08 2002-03-14 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
FR2821556B1 (fr) * 2001-03-02 2003-04-25 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
FR2813793B1 (fr) * 2000-09-08 2003-01-24 Aventis Pasteur Utilisation de lipopeptides pour l'immunotherapie des sujets vih+
EP1911461B1 (de) * 2000-10-19 2011-12-07 Epimmune Inc. HLA-Klasse-I- und -Klasse-II-bindende Peptide und ihre Verwendungen
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
FR2820425B1 (fr) * 2001-02-08 2004-01-02 Commissariat Energie Atomique Melange de peptides issus d'une proteine nef et leurs applications
ATE494909T1 (de) * 2002-11-20 2011-01-15 Bestewil Holding Bv Zusammensetzungen mit antigen-komplexen,verfahren zu ihrer herstellung und verfahren zur verwendung derantigen-komplexe zur vakzinierung
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
AU2010222930B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
CA2754862C (en) 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
PE20151717A1 (es) 2009-11-23 2015-11-19 Cubist Pharm Inc Compuestos lipopeptidos y metodos relacionados
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CA2923595C (en) * 2012-05-18 2020-07-14 Tufts Medical Center, Inc. Polypeptide and lipophilic moiety conjugate compositions, formulations, and uses related thereto
EP3992210A1 (de) 2014-01-13 2022-05-04 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
FR3086534B1 (fr) * 2018-10-01 2020-11-06 Univ Bordeaux Methode pour traiter une infection par le virus de l'immunodeficience humaine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0349354A1 (de) * 1988-04-01 1990-01-03 Institut Pasteur Peptide PF10 bis PF19 von einem Retrovirus HIV, Verfahren zur Synthese dieser Peptide und ihre Verwendung, insbesondere zur Diagnose
FR2670787B1 (fr) * 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1996040213A1 (en) * 1995-06-07 1996-12-19 Cytel Corporation Manufacture and purification of peptides
FR2735478B1 (fr) * 1995-06-13 1997-08-22 Pasteur Institut Molecules polypeptidiques de stade pre-erythrocytaire du paludisme

Also Published As

Publication number Publication date
WO1999027954A2 (fr) 1999-06-10
US7476386B1 (en) 2009-01-13
FR2771640B1 (fr) 2000-02-11
AU1440099A (en) 1999-06-16
ES2265672T3 (es) 2007-02-16
WO1999027954A3 (fr) 1999-08-26
CA2312043A1 (fr) 1999-06-10
JP2002506001A (ja) 2002-02-26
FR2771640A1 (fr) 1999-06-04
EP1035866A2 (de) 2000-09-20
DE69834574D1 (de) 2006-06-22
EP1035866B1 (de) 2006-05-17
DE69834574T2 (de) 2007-05-16

Similar Documents

Publication Publication Date Title
ATE326237T1 (de) Miscmicellen aus lipopeptiden für induzierung einer immunantwort
NO954320D0 (no) Lyosfærer omfattende gonadotropin
ATE273320T1 (de) Fusogene liposomen
NO883395D0 (no) Mikrobicid mikroemulsjon.
NO20002800L (no) Cyklosporinholdig mikroemulsjon, for konsentratsammensetning
DE3850088D1 (de) Integriertes, primäres Fluganzeigeinstrument.
BR0014282A (pt) Vacinas
ITFI920052A0 (it) Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
CY1109710T1 (el) Επιτοπα βοηθητικων τ λεμφοκυτταρων
GR3032543T3 (en) Signal transmission and tag power consumption measurement circuit for an inductive reader.
FR2718706B1 (fr) Structure anti-étincelage, notamment pour aéronef.
CR6683A (es) Sistema de entrega de quelator de hierro
DE3869905D1 (de) Siliciumdioxyd fuer zahnpasten, insbesondere vertraeglich mit chlorhexidin.
TR26619A (tr) YENI BILESIKLER,BUNLARIN HAZIRLANMALARINA YÖNELIK ISLEMLER,BUNLARI ICEREN BILESIMLER VE BUNLARIN ZARARLI OT ÖLDüRüCüSü(HERBISIDAL) OLARAK KULLANI- MI.
DE68920302D1 (de) Lösemittelfreie Silikonzusammensetzungen für Trennpapier.
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DE68911164T2 (de) Filmformende Polysiloxanmikroemulsion.
IT9067679A0 (it) Apparecchiatura per manipolare pile di articoli, ad esempio per caricare maniche o simili in macchine cucitrici.
IT8220995V0 (it) Confezione per la presentazione di indumenti in genere, in particolare di biancheria intima, o di altri prodotti, per uso personale.
DE58903402D1 (de) Magnetsystem fuer schnellabschaltung.
FI911425A0 (fi) Skrivare eller annan motsvarande utmatningsanordning.
IT9047856A0 (it) Apparecchiatura per il confezionamentoc on carta di libri riviste e simili.
IT211011Z2 (it) Monoblocco, isola cucina-soggiorno.
NO884448D0 (no) Ny boelgelederutforming for aa forbedre boelgelederlaserydelse.
FI910814A (fi) Slutet pressparti foer torkmaskin foer cellulosa (eller motsvarande).

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties